OREANDA-NEWS. Takeda Pharmaceutical Company Limited today announced that it has decided the candidates for new Directors which will be proposed to the 140th Ordinary General Meeting of Shareholders on June 29, 2016. Takeda previously announced to change its corporate governance system to a Company with Audit and Supervisory if the transition is approved by the shareholders' meeting. The candidates are as follows;

1. Candidates for Non-Audit and Supervisory Committee Directors

Name

Category

Current Role

Yasuchika Hasegawa

Internal

Existing

Director, Chairman of the Board

Christophe Weber

Internal

Existing

Representative Director,

President & Chief Executive Officer

Shinji Honda

Internal

Existing

Senior Managing Director, Corporate Strategy Officer

Masato Iwasaki

Internal

Existing

Director, President, Japan Pharma Business Unit

Andrew Plump

Internal

Existing

Director, Chief Medical & Scientific Officer

Fumio Sudo

Outside

Existing

Outside Director

Masahiro Sakane

Outside

Existing

Outside Director

Michel Orsinger

Outside

New

(Former head of Global Orthopedics Group, Depuy Synthes Companies, Johnson & Johnson)

Toshiyuki Shiga

Outside

New

(Vice- Chairman, Nissan Motor Co., Ltd.)

Emiko Higashi

Outside

New

(Managing Director, Tomon Partners, LLC)

Yoshiaki Fujimori

Outside

New

(Director, Representative Executive Officer, President and CEO, LIXIL Group Corporation)

2. Candidates for Audit and Supervisory Committee Directors

Name

Category

Current Role

Yasuhiko Yamanaka

Internal

New

Corporate Auditor

Shiro Kuniya

Outside

New

Outside Corporate Auditor

Koji Hatsukawa

Outside

New

(Certified Public Accountant)

Jean-Luc Butel

Outside

New

(Global Healthcare Advisor, President, K8 Global Pte. Ltd.)